Analyzing AquaBounty Technologies (NASDAQ:AQB) and Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for Tyra Biosciences and AquaBounty Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1	0	5	1	2.86
AquaBounty Technologies	1	0	0	0	1.00

Tyra Biosciences currently has a consensus target price of $33.17, indicating a potential upside of 30.22%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than AquaBounty Technologies.

Volatility and Risk

Tyra Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Institutional and Insider Ownership

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 15.2% of Tyra Biosciences shares are owned by company insiders. Comparatively, 2.2% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Tyra Biosciences and AquaBounty Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$86.48 million	($1.87)	-13.62
AquaBounty Technologies	$2.47 million	1.45	-$149.19 million	($0.83)	-1.11

Tyra Biosciences has higher earnings, but lower revenue than AquaBounty Technologies. Tyra Biosciences is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tyra Biosciences and AquaBounty Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-35.76%	-33.58%
AquaBounty Technologies	N/A	-553.11%	-283.83%

Summary

Tyra Biosciences beats AquaBounty Technologies on 9 of the 13 factors compared between the two stocks.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.